Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXDX-107 in advanced or metastatic solid cancer
NCT02548390Phase 1Terminated
- Sponsor
- Roche
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Nanoparticles, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bendamustine dodecyl ester in solid tumor, sponsored by Roche. Primary endpoints: Safety profile of RXDX-107 as characterized by Adverse Events, ECG and laboratory abnormalities at 1 year, Maximum observed plasma drug concentration at 1 year and 7 more. Started Sep 2015; status: terminated.
02
Drugs
bendamustine dodecyl ester
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02548390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02548390.